EF Hutton analyst Michael King reiterates Agenus (NASDAQ:AGEN) with a Buy and maintains $8.3 price target.
Kadmon’s REZUROCK Scores Quick FDA Win For Chronic Graft-Versus-Host Disease
Friday afternoon, the FDA approved Kadmon Holdings Inc’s (NASDAQ:KDMN) REZUROCK to treat chronic graft-versus-host disease (cGVHD), a serious complication of transplant…
